glp 1 pancreatic cancer risk Glucagon-like peptide receptor agonists and risk: advancing precision medicine through mechanistic understanding and clinical evidence | Biomarker Research OR | Early GLP-1 Agonist

NCT03028740)

Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T

With enlicitide, eligible patients now have a once-daily oral option, which could significantly improve treatment adherence and expand access to advanced lipid-lowering therapy

Typically, those who should avoid GLP-1s are those with: A personal or family history of certain thyroid cancers Multiple endocrine neoplasia syndrome type 2 A history of pancreatitis Severe gastroparesis (delayed stomach emptying) Pregnancy or plans to become pregnant Additionally, if you have a history of eating disorders, severe depression or unrealistic weight loss expectations, its important to address these concerns with your physician before considering medication

Niketa is incredibly knowledgeable and intuitive its almost as if she understands your concerns before you even voice them